TheCRE.com
CRE Homepage About The CRE Advisory Board Newsletter Search Links Representation Comments
Reg Week Archives
Data Access
Data Quality
Regulation by Litigation
Regulation by Information
Regulation by Appropriation
Special Projects
CRE Watch List
Emerging Regulatory Issues
Litigation
OMB Papers
Abstracts and Reviews
Guest Column
Voluntary Standards Program
CRE Report Card
Public Docket Preparation
Interactive Public Docket
Electronic Regulatory Reform
Consumer Response Service
Interactive Public Docket
Docket Service
Docket Service
Featured Items on TheCRE.com

National Archives Interview March 2009: Centralized Regulatory Review NOW LIVE
Seven Game Changers
History of Centralized Regulatory Review
Policy Entrepreneurs
A Syllabus on OIRA

®:
CRE's Regulatory Action
of the Week


FDA Extends Comment Period on Opioid Drug Products Meeting
The U.S. Food and Drug Administration has extended the comment period for the public meeting on Pre-Market Evaluation of Abuse-Deterrent Properties of Opioid Drug Products that was announced in the Federal Register on October 6, 2016. In that Federal Register notice, FDA requested comments on the approach to testing FDA recommended in its draft guidance "General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products" and on FDA's efforts to develop standardized in vitro testing methodologies for evaluating the abuse deterrence of opioid drug products. In response to requests for an extension, FDA is extending the comment period to January 3, 2017.

  • Click here for more information on this FDA action..
  •    


    disclaimer
    Copyright Notice The Center for Regulatory Effectiveness [Copyright © 2007]. All right reserved.